Colonic Adenoma: Natural History

Hoff, Geir; Vatn, Morten H.

doi:10.1159/000171293

Cited by 11 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is now a commonly accepted concept that most CRCs develop from pre-existing adenomatous polyps located in the bowel wall. 12,13 Adenomas are particularly common in older age groups, and around one-third of people will develop at least one adenoma by the age of 60 years. 14 Most adenomatous polyps are asymptomatic and remain undiagnosed, and most do not develop into cancer.…”

Section: Chaptermentioning

confidence: 99%

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

Tappenden

Jones²,

Paisley³

et al. 2007

Health Technol Assess

117

View full text Add to dashboard Cite

The trials indicate that bevacizumab in combination with 5-FU/FA, and bevacizumab in combination with IFL, is clinically effective in comparison to standard chemotherapy options for the first-line treatment of metastatic CRC. The health economic analysis suggests that the marginal cost-utility of bevacizumab plus IFL versus IFL is unlikely to be better than pound 62,857 per QALY gained, and the marginal cost-utility of bevacizumab plus 5-FU/FA versus 5-FU/FA is unlikely to be better than pound 88,658 per QALY gained. There is no direct evidence to demonstrate whether cetuximab in combination with irinotecan improves health-related quality of life or OS in comparison to active/best supportive care or oxaliplatin plus 5-FU/FA, although the evidence on tumour response rates suggests that cetuximab plus irinotecan has some clinical activity. While it is difficult to suggest whether cetuximab represents value for money, indirect comparisons suggest that the incremental cost-utility of cetuximab plus irinotecan is unlikely to be better than pound 30,000 per QALY gained. This review highlights a number of areas for further research, including clarifying the true impact of first-line bevacizumab in combination with irinotecan and/or infusional 5-FU/FA, without subsequent bevacizumab treatment following disease progression, on OS in patients with metastatic CRC who are representative of the typical population of CRC patients in England and Wales. Further research concerning the impact of therapies on health-related quality of life is essential.

show abstract

Section: Chaptermentioning

confidence: 99%

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

Tappenden

Jones²,

Paisley³

et al. 2007

Health Technol Assess

117

View full text Add to dashboard Cite

show abstract

“…It is thought that most colorectal cancers develop from adenomas [3,4], and some evidence suggests that they may be present for 10 years or more before malignancy develops [5,6]. Their size and number, histological type and degree of epithelial dysplasia are thought to affect the risk of colorectal cancer.…”

Section: Introductionmentioning

confidence: 99%

Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta-analysis

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In fact, even though the prevalence of adenomas in most high-risk populations is extremely high (as high as 20 percent in people under 50 and over 50 percent among people in their 70s [16], colorectal cancer is still a rare event. Estimates of the cumulative risk of invasive cancer after adenoma detected on screening exam range from 1 to 10 percent depending on the length of follow-up [16,17]. Apart from pathologic characteristics such as larger size and villous histology, little is known about risk factors for intermediate steps along the adenoma-carcinoma sequence such as carcinoma in situ (CIS) and intramucosal carcinoma [18].…”

Section: Introductionmentioning

confidence: 99%

Tobacco, alcohol, and p53 overexpression in early colorectal neoplasia

et al. 2003

View full text Add to dashboard Cite

Background: The p53 tumor suppressor gene is commonly mutated in colorectal cancer. While the effect of p53 mutations on colorectal cancer prognosis has been heavily studied, less is known about how epidemiologic risk factors relate to p53 status, particularly in early colorectal neoplasia prior to clinically invasive colorectal cancer (including adenomas, carcinoma in situ (CIS), and intramucosal carcinoma).

show abstract

Colonic Adenoma: Natural History

Cited by 11 publications

References 21 publications

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta-analysis

Tobacco, alcohol, and p53 overexpression in early colorectal neoplasia

Contact Info

Product

Resources

About